Recruiting Clinical Trials

Displaying 31 - 34 of 34 result(s)
Study Title Condition Phase Location
An Open-label, Multi-center Protocol for Patients Who Have Completed a Previous Novartis Sponsored Secukinumab Study and Are Judged by the Investigator to Benefit From Continued Secukinumab Treatment Autoimmunity, Inflammation Phase 4
  • Country: 
    United States
  • Country: 
    Bulgaria
  • Country: 
    Czech Republic
  • Country: 
An Open-label, Non-randomized Extension Study to Evaluate the Long Term Safety, Tolerability, Efficacy and Pharmacokinetics of CDZ173 in Patients With APDS/PASLI (Activated Phosphoinositide 3-kinase Delta Syndrome/p110δ-activating Mutation Causing Se ... Activated PI3Kdelta Syndrome (APDS); PASLI Disease Phase 2, Phase 3
  • Country: 
    Belarus
  • Country: 
    Czech Republic
  • Country: 
    Germany
  • Country: 
A Multicenter, Double-blind, Randomized Withdrawal Extension Study of Subcutaneous Secukinumab to Demonstrate Long-term Efficacy, Safety and Tolerability in Subjects With Moderate to Severe Hidradenitis Suppurativa Hidradenitis Suppurativa Phase 3
  • Country: 
    United States
  • Country: 
    Argentina
  • Country: 
    Australia
  • Country: 
A Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase III Multicenter Study of Intravenous Secukinumab to Compare Efficacy at 16 Weeks With Placebo and to Assess Safety and Tolerability up to 52 Weeks in Subjects With Active Ankylosin ... Ankylosing Spondylitis or Non-radiographic Axial Spondyloarthritis Phase 3
  • Country: 
    United States
  • Country: 
    Belgium
  • Country: 
    Brazil
  • Country: